Methods for the Recovery and Purification of Polyene Antifungals

REFERENCES

• Prentice H. G., Hann I. M., Herbrecht R., Aoun M., Kvaloy S., Catovsky D., Pinkerton C. R., Schey S. A., Jacobs F., Oakhill A., Stevens R. F., Darbyshire P. J., Gibson B. E. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. 1997; 98: 711–718
   PubMed Web of Science ®Google Scholar
• Demarie S. New developments in the diagnosis and management of invasive fungal infections. Haematologica 2000; 85: 88–93
   PubMedGoogle Scholar
• Bekersky I., Boswell G. W., Hiles R., Fielding R. M., Buell D., Walsh T. J. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBiosome®) in beagle dogs. Pharm. Res. 1999; 16: 1694–1701
   PubMed Web of Science ®Google Scholar
• Moribe K., Maruyama K., Iwatsuru M. Encapsulation characteristics of nystatin in liposomes: effects of cholesterol and polyethylene glycol derivatives. Int. J. Pharm. 1999; 188: 193–202
   PubMed Web of Science ®Google Scholar
• Vandeputte J., Wachtel J. L., Stiller E. T. Amphotericins A and B, antifungal antibiotics produced by a Streptomycete. Antibiot. Ann. 1956–1957; 587–591
   Google Scholar
• Boswell G. W., Buell D., Bekersky I. AmBiosome (liposomal amphotericin B): a comparative review. J. Clin. Pharmacol. 1998; 38: 583–592
   PubMed Web of Science ®Google Scholar
• Diehl K. B. Topical antifungal agents: an update. Am. Fam. Phys. 1996; 54: 1687–1692
   PubMed Web of Science ®Google Scholar
• Barrett J. P., Ramzy P. I., Heggers J. P., Villareal C., Herndon D. N., Desai M. H. Topical nystatin powder in severe burns: a new treatment for angioinvasive fungal infections refractory to other topical and systemic agents. Burns 1999; 25: 505–508
   PubMed Web of Science ®Google Scholar
• Groll A. H., Gonzalez C. E., Giri N., Kligys K., Love W., Peter J., Feuerstein E., Bacher J., Piscitelli S. C., Walsh T. J. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics. J. Antimicrob. Chemother. 1999; 43: 95–103
   PubMed Web of Science ®Google Scholar
• Carillo-Munoz A. J., Quindos G., Tur C., Ruesga M. T., Miranda Y., del Valle O., Cossum P. A., Wallace T. L.J. In vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. Antimicrob. Chemother. 1999; 44: 397–401
   Web of Science ®Google Scholar
• Hardin T. C. In search of an ideal systemic antifungal agent. J. Infect. Dis. Pharmacother. 1998; 3: 69–83
   Google Scholar
• Hacene H., Kebir K., Othmane D. S., Lefebvre G. HM17, a new polyene antifungal antibiotic produced by a new strain of Spirillospora. J. Appl. Bacteriol. 1994; 77: 484–489
   PubMedGoogle Scholar
• Itoh A., Ido J., Iwamoto Y., Goshima E., Miki T., Hasuda K., Hirota H. YS-822A, a new polyene macrolide antibiotic. I. Production, isolation, characterization and biological properties. J. Antibiot. (Tokyo) 1990; 43: 948–955
   PubMed Web of Science ®Google Scholar
• Rahman M. R., Johnson G. J., Husain R., Howlader S. A., Minassian D. C. Randomised trial of 0.2% chlorhexidine gluconate and 2.5% natamycin for fungal keratitis in Bangladesh. Br. J. Ophthalmol. 1998; 82: 919–925
   PubMed Web of Science ®Google Scholar
• Aho R., Tala M., Kivalo M. Mycotic keratitis in a horse caused by Aspergillus fumigatus. The first reported case in Finland. Acta Vet. Scand. 1991; 32(3)373–376
   PubMed Web of Science ®Google Scholar
• Harindran J., Chakraborty K. K., Naik S. K. Preparation, relative toxicity and therapeutic efficacy in mice and rats of liposomal HA-1-92, a new oxohexaene polyene macrolide antibiotic. J. Pharm. Pharmacol. 1999; 51: 771–776
   PubMed Web of Science ®Google Scholar
• Pessina A., Rossoni L., Piccirillo M., Sala G., Neri M. G. Preliminary study on in vitro activity and cytotoxicity on cell cultures of a new polyene antifungal molecule (SPA-843). Eur. J. Pharm. Biopharm. 1999; 47: 179–184
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Mehta R., Hopfer R., Mehta K., Hersh E. M., Juliano R. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Del. 1983; 1: 37–42
   PubMedGoogle Scholar
• Teresin I. M. Polyene Antibiotics—Present and Future. University of Tokyo Press, Tokyo 1976; 122–123
   Google Scholar
• Thoma K., Kubler N. Photostability of antifungal agents. 2. Photostability of polyene antibiotics. Pharmazie 1997; 52: 294–302
   PubMedGoogle Scholar
• Oki T. Pramicidin, a novel antifungal. New Approaches for Antifungal Drugs, P. B. Fernandes. Birkhauser, Boston 1992; 64–87
   Google Scholar
• Shenin Y. D., Kotenko T. V., Exemplyarov O. N. Komponentnyi sostav nistatin. Antibiotiki (Moscow) 1968; 13: 387–411
   Google Scholar
• Michel G. W. Nystatin. Analytical Profiles of Drug Substances, K. Florey. Academic Press, New York 1977; 6: 341–421
   Google Scholar
• Borowski E., Zielinski J., Ziminski T., Falkowski L., Kolodziejczyk P., Golik J., Jereczek E. Chemical studies with amphotericin B. 3. The complete structure of the antibiotic. Tetrahedron Lett 1970; 45: 3909–3914
   PubMedGoogle Scholar
• Foucault A. P., Chevolot L. Counter-current chromatography: instrumentation, solvent selection and some recent applications to natural product purification. J. Chromatography A 1998; 808: 3–22
   Web of Science ®Google Scholar
• Gold W., Stout H. A., Pagano J. F., Donovick R. Amphotericins A and B, antifungal antibiotics produced by a Streptomycete. Antibiot. Ann. 1956; 579–586
   Google Scholar
• Dutcher J. D., Gold W., Pagano J. F., Vandeputte J. Amphotericin B, its production and its salts. U.S. Patent 2,908,611, 1959
   Google Scholar
• Leningrad Scientific Research Institute of Antibiotics USSR. Purification of amphotericin B. J.P. 53043515, 1978
   Google Scholar
• Etingov E. D., Kul'bach V. O., Nyn V. S., Malkov M. A. Amphotericin B. Soviet Patent SU 271,725, 1979
   Google Scholar
• Kul'bach V. O., Etingov E. D., Nyn V. S., Malkov M. A. Purification of amphotericin B. Ger. Offen. DE 2,121,517, 1972
   Google Scholar
• Michel G. W., Bryan W. L., Bryan E. Process and composition for the purification of amphotericin B. U.S. Patent 4,902,789, 1990
   Google Scholar
• Kul'bach V. O., Etingov E. D., Nyn V. S., Malkov M. A. Chemically purifying amphotericin B. British Patent GB 1,298,172, 1972
   Google Scholar
• Etingov E. D., Kul'bach V. O., Nyn V. S., Malkov M. A. Recovery and chemical purification of amphotericin B. Fr. Demande FR 2,173,632, 1973
   Google Scholar
• Peterson N. O., Henshaw P. F. Separation of fluorescent impurities from amphotericin B. Can. J. Chem. 1981; 59: 3377–3378
   Google Scholar
• Zografi G., Schott H., Swarbrick J. Disperse systems. Remington's Pharmaceutical Sciences, A. R. Gennaro. 18th Ed., Mack Publishing Co., Easton, PA 1990; 293–294
   Google Scholar
• Vold R. D., Vold M. J. Colloid and Interface Chemistry. Addison-Wesley, Reading, MA 1983
   Google Scholar
• Metzger J. Water-soluble amphotericin B complexes. Ger. Offen. DE 2,255,224, 1973
   Google Scholar
• Michel G. W., Fralick E. A. Process for the purification of amphotericin B and A solubilizing media useful in that process. U.S. Patent 4,177,265, 1979
   Google Scholar
• Ko R. Y., Szarka L. J. Formation of amphotericin B crystals in fermentation broth by heating and optionally enzyme treatment or seeding. U.S. Patent 4,748,117, 1988
   Google Scholar
• Tang W. W. Purifying water-insoluble polyene antibiotics. U.S. Patent 4,308,375, 1981
   Google Scholar
• Rees M. J., Cutmore E. A., Verrall M. A. Isolation of amphotericin B by liquid ion exchange extraction. Spec. Publ. Royal Soc. Chem. (Separations for Biotechnology 3) 1994; 158: 399–405
   Google Scholar
• Ghielmett G., Bruzzese T., Bianchi C., Recusani F. Relationship between acute toxicity in mice and polymorphic forms of polyene antibiotics. J. Pharm. Sci. 1976; 65: 905–907
   PubMed Web of Science ®Google Scholar
• Klein A. E. States ofmatter. Physical Pharmacy, A. Martin. 4th Ed., Lea & Febiger, Malvern, PA 1993; 33–36
   Google Scholar
• Moreno M. A., Frutos P., Ballesteros M. P. Extraction and liquid-chromatographic determination of amphotericin B in oil-water lecithin-based microemulsions. Chromatographia 1998; 48: 803–806
   Web of Science ®Google Scholar
• Stewart K. R., Gentile J., Platt T. B., Stewart K. A., Swenson C. E. Solid-phase extraction method for the separation of amphotericin B from the lipids dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol. Analyst (London) 1989; 114: 1381–1384
   Web of Science ®Google Scholar
• Ishii K., Sugimoto R., Myashiro S. Method for purification of polyene antibiotic methyl esters. Kokai Tokkyo Koho Japanese Patent JP 05059084, 1993
   Google Scholar
• Schaffner C. P., Kientzler D. J. Improved process for the production of amphotericin B. World Patent WO 9707231, 1997
   Google Scholar
• Hazen E. I., Brown R. Two antifungal agents produced by a soil actinomycetes. Science 1950; 112: 423
   PubMed Web of Science ®Google Scholar
• Renella J. G. Isolation of nystatin. U.S. Patent 3,517,100, 1970
   Google Scholar
• Kubec K., Pesek M., Culik K., Benda A., Hilbert O. Crystalline fungicidin. Czech. Patent CS 231,653, 1986
   Google Scholar
• Vandeputte J., Nager U. F. Isolation of nystatin. U.S. Patent 3,332,844, 1967
   Google Scholar
• Riga Plant for Medical Preparations, USSR. Extraction of nystatin with methyl alcohol. Soviet Patent SU 130626, 1978
   Google Scholar
• Jarai M., Kegl L., Kocsis G., Lokietek W., Reiber E. Pato, Piukovich S., Udvardy A., Zlatos G. Crystalline, suspendable nystatin from fermentation products. Hungarian Patent HU 55026, 1991
   Google Scholar
• Kleiners G., Iazdina V., Trakhtenberg D. M. Extraction of the fungicidal antibiotic nystatin from Streptomyces noursei mycelium. Soviet Patent SU 135186, 1977
   Google Scholar
• Nanescu G., Luca S., Moscovici M., Ciobanu I., Sauciuc A., Albu M., Tudose C., Halpern E., Manasii A. Isolation and purification of nystatin. Romanian Patent RO 69992, 1980
   Google Scholar
• Culik K., Pelzbauer J., Kalina V., Benda A. Isolation of fungicidin. Czech. Patent CS 155,064, 1974
   Google Scholar
• Maidanov V. V., Egutkin N. L., Nikiti Y. E. Nystatin extraction from mycelium with dimethylsulfoxide. Antibiotiki (Moscow) 1983; 28: 502–504
   PubMedGoogle Scholar
• Lokshin G. B., Zhdanovich Y. V., Kuzovkov A. D., Volkova T. I., Shtamer Y. V., Kleiner G. I. Mechanism of polyenic antibiotics inactivation. Stability of nystatin on prolonged storage. Antibiotiki (Moscow) 1967; 12: 196–200
   PubMedGoogle Scholar
• Mendelsohn H. Highly purified crystalline nystatin. U.S. Patent 3,509,255, 1970
   Google Scholar
• Keseleski K. J., Michel G. W. Recrystallization process for the purification of nystatin. U.S. Patent 3,911,113, 1975
   Google Scholar
• Metzger J. Purification of nystatin. U.S. Patent 4,006,222, 1977
   Google Scholar
• Metzger J. Purification of nystatin in an aqueous system. U.S. Patent 4,185,092, 1980
   Google Scholar
• Oita N., Cojocaru M., Lazar M. Nystatin injection. Romanian Patent 86,718, 1985
   Google Scholar
• Sauer B., Matusch R. High-performance liquid chromatographic separations of nystatin and their influence on the antifungal activity. J. Chromatography A 1994; 672: 247–253
   PubMed Web of Science ®Google Scholar
• Milhaud J., Gareil P., Rosset R. Separation of filipin and nystatin complexes by semi-preparative and microbore high-performance liquid chromatography. J. Chromatography 1986; 16: 284–287
   Google Scholar
• Jensen T. B., Reijns T. G.P., Billiet H. A.H., van der Wielen L. A.M. Novel simulated moving-bed method for reduced solvent consumption. J. Chromatography A 2000; 873: 149–162
   PubMed Web of Science ®Google Scholar
• Worthen D. R., Jay M., Bummer P. M. Foam fractionation for the separation and purification of dimyristoyl lipids and nystatin from complex mixtures. AAPS Pharm-Sci. (Suppl.) 1999; 1: S–3261
   Google Scholar
• Lockwood C. E., Bummer P. M., Jay M. Purification 286 Worthen, Jay, and Bummer of proteins using foam fractionation. Pharm. Res. 1997; 14: 1511–1515
   PubMed Web of Science ®Google Scholar
• Lockwood C. E., Kim S. H., Bummer P. M., Jay M. Scintigraphic measurement of liquid holdup in foam fractionation columns. J. Colloid Interface Sci. 2000; 227: 24–31
   PubMed Web of Science ®Google Scholar
• Clark A. M. The need for new antifungal drugs. New Approaches for Antifungal Drugs, P. B. Fernandes. Birkhauser, Boston, MA 1992; 1–19
   Google Scholar
• Kaufman C. A. Systemic antifungal agents: what is in the pipeline?. Drugs R&D 1999; 1: 153–159
   PubMedGoogle Scholar
• Travkin O. V., Lashkov G. I., Komarov E. V. Physicochemical characteristics of the three states of the nystatin molecule. Antibiotiki (Moscow) 1981; 26: 519–522
   PubMedGoogle Scholar